CDK4 Human siRNA Oligo Duplex (Locus ID 1019)
CAT#: SR319663
CDK4 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
SR319663 is the updated version of SR300734.
CNY 4,090.00
货期*
4周
规格
Cited in 2 publications. |
Product images
经常一起买 (3)
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_000075, NM_052984 |
Synonyms | CMM3; PSK-J3 |
Components | CDK4 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1019)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
MicroRNA-195 inhibits epithelial-mesenchymal transition via downregulating CDK4 in bladder cancer
,Chen, S;Wang, W;Lin, G;Zhong, S;,
Int J Clin Exp Pathol
[CDK4]
|
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
,Wood, AC;Krytska, K;Ryles, HT;Infarinato, NR;Sano, R;Hansel, TD;Hart, LS;King, FJ;Smith, TR;Ainscow, E;Grandinetti, KB;Tuntland, T;Kim, S;Caponigro, G;He, YQ;Krupa, S;Li, N;Harris, JL;Mossé, YP;,
Clin. Cancer Res.
,PubMed ID 27986745
[CDK4]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...